SeraCare Life Sciences Inc., a Milford-based life sciences company, said that its board of directors has started a process to explore and evaluate potential strategic alternatives for the company to enhance shareholder value.
Possible options include a sale or other transaction, SeraCare said in a press release.
There is no set timetable for the process, said SeraCare, which added that it does not intend to provide updates or make any further comments regarding the evaluation of strategic alternatives unless a specific transaction is recommended by the board.
On July 26, the company said that Susan Vogt, previously chief executive of SeraCare, is no longer with the company; Greg Gould was named interim CEO. Gould continues in his role as chief financial officer.